Mywy (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

Drospirenone/Ethinylestradiol, the active ingredients in Mywy, are a combined oral contraceptive presented as a tablet for oral use. They work by inhibiting ovulation and creating cervical mucus changes, thereby preventing pregnancy in women of reproductive age who are seeking reliable hormonal birth control.

GNH USA supplies Mywy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products for global healthcare markets, and adhering to stringent regulatory standards, with reliable supply chains and on‑time delivery.

Mywy, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy. - Prevention of pregnancy: Provides reliable, reversible contraception for women of child‑bearing potential. - Management of menstrual disorders: Helps regulate irregular bleeding and reduce dysmenorrhea when prescribed. - Reduction of ovarian cyst formation: Decreases the risk of functional ovarian cysts in women using hormonal contraception.

Common Side Effects: - Nausea: Mild to moderate stomach upset. - Breast tenderness: Sensitivity or swelling of the breasts. - Headache: Tension‑type or migraine‑like pain. - Spotting: Light bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: Blood clots in deep veins or lungs. - Arterial thrombosis: Stroke or heart attack risk. - Severe hypertension: Sudden high blood pressure. - Liver disorders: Jaundice or abnormal liver enzymes. - Allergic reactions: Rash, swelling, or anaphylaxis. - Severe depression or mood changes: Persistent sadness or suicidal thoughts.

Before prescribing Mywy, clinicians should evaluate individual risk factors and contraindications. - Assess cardiovascular risk: Review history of thromboembolism, hypertension, or smoking. - Screen for liver disease: Avoid use in active hepatic impairment. - Evaluate hormone‑sensitive conditions: Contraindicated in estrogen‑dependent tumors. - Counsel on missed doses: Provide guidance on backup contraception. - Store at below 25°C: Keep tablets in the original pack, protect from moisture and direct light.

Mywy may interact with several medicines that affect its efficacy or safety. Major Interactions (Avoid): - Strong enzyme inducers (e.g., rifampin, carbamazepine): May reduce contraceptive effectiveness. - Combined hormonal therapy for breast cancer: Contraindicated due to estrogen exposure. Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): Can increase hormone levels, raising side‑effect risk. - Certain antibiotics (e.g., tetracycline): May slightly diminish contraceptive reliability. - St. John’s wort: Herbal supplement that may lower plasma hormone concentrations.